Oncology

HT Vet's new VISTA iQ uses AI to screen dog lumps in 40 seconds, aiming to save lives and transform the financial health of veterinary practices.

The global CRO is acquiring specialized firm Catalyst Clinical Research, aiming to dominate the booming oncology trial market. But can it navigate the risks?

For 10 years, McKesson's QCDR has helped oncologists navigate MIPS. Now, new measures aim to elevate patient care and prove the value of treatment.

GSK's subsidiary Tesaro inks a deal worth up to $285M with Alteogen to create an under-the-skin version of its cancer drug Jemperli.

The world's top cancer center partners with IBA in a multi-million dollar deal to install three advanced Proteus®ONE systems, heralding a new era.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

New legislation, SB 1165, could save lives by eliminating out-of-pocket costs for diagnostic breast imaging, a financial burden forcing many to delay care.

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

A first-in-class immunotherapy, UNLOXCYT™, offers a new lifeline for patients with advanced skin cancer, made accessible through a key national partnership.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

The global digital immunoassay market is set to triple, promising to find diseases earlier than ever. But can healthcare systems overcome the high cost?

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

A new partnership aims to make life-saving cancer and anti-infective drugs stable at room temperature, revolutionizing global access and sustainability.

A sudden collapse led to a rare cancer diagnosis for a NJ teen. His story of recovery highlights a therapy that targets tumors while sparing young minds.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

Eagle Pharmaceuticals divests its unique post-op nausea drug to France's LXO Group, signaling a strategic pivot to oncology and critical care.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With $11.1M from industry giants, a Palo Alto startup is deploying an AI to automate prior authorizations and get cancer patients on therapy faster.

The AI health-tech leader achieved profitability and massive growth in 2025, expanding its reach to nearly 2,000 hospitals and doubling its life sciences arm.